SynthesisJournal of cancer research and clinical oncology2011
ERCC2 Lys751Gln and Asp312Asn polymorphisms and gastric cancer risk: a meta-analysis.
Synthesis in Journal of cancer research and clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 4 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Pooled it
- Glutathione S-transferase P1 gene polymorphism and bladder cancer susceptibility: an updated analysis.Molecular biology reports · 2013Pooled it
- Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis.PloS one · 2012Pooled it
- The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis.PloS one · 2012Pooled it
- Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis.Oncotarget · 2017Review
- Association of single nucleotide polymorphisms in ERCC2 gene and their haplotypes with esophageal squamous cell carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStudies investigating the association between excision repair cross-complimentary group 2 (ERCC2) polymorphisms and gastric cancer (GC) risk have reported conflicting results. We performed a meta-analysis of published epidemiological studies to derive a more precise estimation of the relationship.
methodsPublished literature from PubMed, EMBASE, and China National Knowledge Infrastructure was retrieved. Ten studies with 2,141 GC cases and 5,343 controls were selected.
resultsNo association between ERCC2 Lys751Gln polymorphism and GC susceptibility for all genetic models was found. When stratified by race, we found the Gln/Gln genotype carriers might be at high risk of GC among Asians, but not among Caucasians. Also, the pooled results showed there was a significant difference in genotype distribution between non-gastric cardia cancer cases and controls. For ERCC2 Asp312Asn polymorphism, significantly elevated GC risk was associated with Asn/Asn genotype (AA vs. GG + GA: OR = 1.36, 95%CI = 1.04-1.77, P = 0.02). We also found this genotype was associated with GC susceptibility among Asians and subjects without Helicobacter pylori infection. No publication bias was found in the present study.
conclusionsThis meta-analysis concluded that both ERCC2 Lys751Gln and Asp312Asn polymorphisms might contribute to increased risk of GC among Asians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.